ARCHIVES

Interim Analysis of Phase III Data Preferable For Accelerated Approval, FDA’s Pazdur Says

This article is from The Cancer Letter archive.

Vol. 28 No. 32 | September 6, 2002

Download PDF Visit The Full Archive

Related Articles

AC To Refuse Government Help In Future Projects

November 24, 1978

NIH-funded HapMap consortium publishes first phase of catalog.

October 28, 2005

CMS Allows Medicare Payment for Eloxatin, But Says Review of New Agents Likely

May 23, 2003

Research teams link response to Iressa to mutations in EGF receptor.

April 30, 2004

NCI advisors approve $50 million pilot for Human Cancer Genome Project; NHLBI Director Collins calls it a “unique, historic opportunity.”

November 18, 2005

HHS Appoints 13 To Genetics Committee

January 17, 2003